The overexpression or mutation of Her2 confers a growth advantage to tumor cells by enhancing the PI3K/Akt “survival” and the MAPK “mitogenic” pathways [1], associating the up-regulation of this receptor to a malignant phenotype. This evidence concerns the gene ERBB2 and neoplasm.